Prophylactic effects of Bacille Calmette-Guérin intravesical instillation therapy: Time period-related comparison between Japan and Western countries-Reference-Cited by-同舟云学术

Prophylactic effects of Bacille Calmette-Guérin intravesical instillation therapy: Time period-related comparison between Japan and Western countries

Published:2013-12-28 Issue:1 Volume:15 Page:
ISSN:1527-2737
Container-title:Current Urology Reports
language:en
Short-container-title:Curr Urol Rep

Author:

Okamura Takehiko,Ando Ryosuke,Akita Hidetoshi,Kawai Noriyasu,Tozawa Keiichi,Kohri Kenjiro,Arano Hideo

Publisher

Springer Science and Business Media LLC

Subject

Urology,General Medicine

Link

http://link.springer.com/content/pdf/10.1007/s11934-013-0374-1.pdf

Reference60 articles.

1. Smith Jr JA, Labasky RF, Cockett AT, Fracchia JA, Montie JE, Rowland RG. Bladder cancer clinical guidelines panel summary report on the management of nonmuscle invasive bladder cancer (stages Ta, T1 and TIS). The American Urological Association. J Urol. 1999;162:1697–701.

2. Oosterlinck W, Lobel B, Jackse G, Malmström PU, Stöckle M, Strenberg C; European Association of Urology. EAU Recommendations 2001. "Guidelines on bladder cancer", 2001.

3. Schwaibold HE, Sivalingam S, May F, Hartung R. The value of a second transurethral resection for T1 bladder cancer. BJU Int. 2006;97:1199–201.

4. Sivalingam S, Probert JL, Schwaibold H. The role of repeat transurethral resection in the management of high-risk superficial transitional cell bladder cancer. BJU Int. 2005;96:759–62.

5. •• Brausi M, Witjes JA, Lamm D, Persad R, Palou J, Colombel M, et al. A review of current guidelines and best practice recommendations for the management of nonmuscle invasive bladder cancer by the International Bladder Cancer Group. J Urol. 2012;186:2158–67. This paper reports a review of most major current guidelines and emphasized the importance of re-TUR for the management of NMIBC..

Cited by 1 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Predictive Markers for the Recurrence of Nonmuscle Invasive Bladder Cancer Treated with Intravesical Therapy;Disease Markers;2015